Selected research
Industry Research
Tumor Necrosis Factor Receptor Superfamily Industry Research Report 2026
Market perspective
The global Tumor Necrosis Factor Receptor Superfamily market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Tumor Necrosis Factor Receptor Superfamily is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Tumor Necrosis Factor Receptor Superfamily is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Tumor Necrosis Factor Receptor Superfamily is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Tumor Necrosis Factor Receptor Superfamily include Ablynx NV, Apogenix GmbH, Bristol-Myers Squibb Company, Five Prime Therapeutics Inc, Incyte Corp, MedImmune LLC, OncoMed Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc and Amgen Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Tumor Necrosis Factor Receptor Superfamily market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Tumor Necrosis Factor Receptor Superfamily Market by Company
Ablynx NV
Apogenix GmbH
Bristol-Myers Squibb Company
Five Prime Therapeutics Inc
Incyte Corp
MedImmune LLC
OncoMed Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Amgen Inc
Merck & Co Inc
Novartis AG
Tumor Necrosis Factor Receptor Superfamily Segment by Type
INCAGN-1876
GWN-323
FPA-154
BMS-986156
AMG-228
Others
Tumor Necrosis Factor Receptor Superfamily Segment by Application
Blood Cancer
Gastric Cancer
Melanoma
Non-Small Cell Lung Cancer
Others
Tumor Necrosis Factor Receptor Superfamily Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor Receptor Superfamily market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor Receptor Superfamily and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor Receptor Superfamily.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Tumor Necrosis Factor Receptor Superfamily manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Tumor Necrosis Factor Receptor Superfamily by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Tumor Necrosis Factor Receptor Superfamily in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- INCAGN-1876
- GWN-323
- FPA-154
- BMS-986156
- AMG-228
- Others
Applications
- Blood Cancer
- Gastric Cancer
- Melanoma
- Non-Small Cell Lung Cancer
- Others
Companies covered
- Ablynx NV
- Apogenix GmbH
- Bristol-Myers Squibb Company
- Five Prime Therapeutics Inc
- Incyte Corp
- MedImmune LLC
- OncoMed Pharmaceuticals Inc
- Regeneron Pharmaceuticals Inc
- Amgen Inc
- Merck & Co Inc
- Novartis AG
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Tumor Necrosis Factor Receptor Superfamily Market Size (2021-2032)
- 2.2.2 Global Tumor Necrosis Factor Receptor Superfamily Sales (2021-2032)
- 2.2.3 Global Tumor Necrosis Factor Receptor Superfamily Market Average Price (2021-2032)
- 2.3 Tumor Necrosis Factor Receptor Superfamily by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 INCAGN-1876
- 2.3.3 GWN-323
- 2.3.4 FPA-154
- 2.3.5 BMS-986156
- 2.3.6 AMG-228
- 2.3.7 Others
- 2.4 Tumor Necrosis Factor Receptor Superfamily by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Blood Cancer
- 2.4.3 Gastric Cancer
- 2.4.4 Melanoma
- 2.4.5 Non-Small Cell Lung Cancer
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Tumor Necrosis Factor Receptor Superfamily Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Tumor Necrosis Factor Receptor Superfamily Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Tumor Necrosis Factor Receptor Superfamily Revenue of Manufacturers (2021-2026)
- 3.4 Global Tumor Necrosis Factor Receptor Superfamily Average Price by Manufacturers (2021-2026)
- 3.5 Global Tumor Necrosis Factor Receptor Superfamily Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Tumor Necrosis Factor Receptor Superfamily, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Tumor Necrosis Factor Receptor Superfamily, Product Type & Application
- 3.8 Global Manufacturers of Tumor Necrosis Factor Receptor Superfamily, Established Date
- 3.9 Global Tumor Necrosis Factor Receptor Superfamily Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Ablynx NV
- 4.1.1 Ablynx NV Company Information
- 4.1.2 Ablynx NV Business Overview
- 4.1.3 Ablynx NV Tumor Necrosis Factor Receptor Superfamily Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Ablynx NV Tumor Necrosis Factor Receptor Superfamily Product Portfolio
- 4.1.5 Ablynx NV Recent Developments
- 4.2 Apogenix GmbH
- 4.2.1 Apogenix GmbH Company Information
- 4.2.2 Apogenix GmbH Business Overview
- 4.2.3 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Product Portfolio
- 4.2.5 Apogenix GmbH Recent Developments
- 4.3 Bristol-Myers Squibb Company
- 4.3.1 Bristol-Myers Squibb Company Company Information
- 4.3.2 Bristol-Myers Squibb Company Business Overview
- 4.3.3 Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Product Portfolio
- 4.3.5 Bristol-Myers Squibb Company Recent Developments
- 4.4 Five Prime Therapeutics Inc
- 4.4.1 Five Prime Therapeutics Inc Company Information
- 4.4.2 Five Prime Therapeutics Inc Business Overview
- 4.4.3 Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Product Portfolio
- 4.4.5 Five Prime Therapeutics Inc Recent Developments
- 4.5 Incyte Corp
- 4.5.1 Incyte Corp Company Information
- 4.5.2 Incyte Corp Business Overview
- 4.5.3 Incyte Corp Tumor Necrosis Factor Receptor Superfamily Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Incyte Corp Tumor Necrosis Factor Receptor Superfamily Product Portfolio
- 4.5.5 Incyte Corp Recent Developments
- 4.6 MedImmune LLC
- 4.6.1 MedImmune LLC Company Information
- 4.6.2 MedImmune LLC Business Overview
- 4.6.3 MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Product Portfolio
- 4.6.5 MedImmune LLC Recent Developments
- 4.7 OncoMed Pharmaceuticals Inc
- 4.7.1 OncoMed Pharmaceuticals Inc Company Information
- 4.7.2 OncoMed Pharmaceuticals Inc Business Overview
- 4.7.3 OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Product Portfolio
- 4.7.5 OncoMed Pharmaceuticals Inc Recent Developments
- 4.8 Regeneron Pharmaceuticals Inc
- 4.8.1 Regeneron Pharmaceuticals Inc Company Information
- 4.8.2 Regeneron Pharmaceuticals Inc Business Overview
- 4.8.3 Regeneron Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Regeneron Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Product Portfolio
- 4.8.5 Regeneron Pharmaceuticals Inc Recent Developments
- 4.9 Amgen Inc
- 4.9.1 Amgen Inc Company Information
- 4.9.2 Amgen Inc Business Overview
- 4.9.3 Amgen Inc Tumor Necrosis Factor Receptor Superfamily Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Amgen Inc Tumor Necrosis Factor Receptor Superfamily Product Portfolio
- 4.9.5 Amgen Inc Recent Developments
- 4.10 Merck & Co Inc
- 4.10.1 Merck & Co Inc Company Information
- 4.10.2 Merck & Co Inc Business Overview
- 4.10.3 Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Product Portfolio
- 4.10.5 Merck & Co Inc Recent Developments
- 4.11 Novartis AG
- 4.11.1 Novartis AG Company Information
- 4.11.2 Novartis AG Business Overview
- 4.11.3 Novartis AG Tumor Necrosis Factor Receptor Superfamily Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Novartis AG Tumor Necrosis Factor Receptor Superfamily Product Portfolio
- 4.11.5 Novartis AG Recent Developments
5 Global Tumor Necrosis Factor Receptor Superfamily Market Scenario by Region
- 5.1 Global Tumor Necrosis Factor Receptor Superfamily Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Tumor Necrosis Factor Receptor Superfamily Sales by Region: 2021-2032
- 5.2.1 Global Tumor Necrosis Factor Receptor Superfamily Sales by Region: 2021-2026
- 5.2.2 Global Tumor Necrosis Factor Receptor Superfamily Sales by Region: 2027-2032
- 5.3 Global Tumor Necrosis Factor Receptor Superfamily Revenue by Region: 2021-2032
- 5.3.1 Global Tumor Necrosis Factor Receptor Superfamily Revenue by Region: 2021-2026
- 5.3.2 Global Tumor Necrosis Factor Receptor Superfamily Revenue by Region: 2027-2032
- 5.4 North America Tumor Necrosis Factor Receptor Superfamily Market Facts & Figures by Country
- 5.4.1 North America Tumor Necrosis Factor Receptor Superfamily Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Tumor Necrosis Factor Receptor Superfamily Sales by Country (2021-2032)
- 5.4.3 North America Tumor Necrosis Factor Receptor Superfamily Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Tumor Necrosis Factor Receptor Superfamily Market Facts & Figures by Country
- 5.5.1 Europe Tumor Necrosis Factor Receptor Superfamily Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Tumor Necrosis Factor Receptor Superfamily Sales by Country (2021-2032)
- 5.5.3 Europe Tumor Necrosis Factor Receptor Superfamily Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Market Facts & Figures by Country
- 5.6.1 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Tumor Necrosis Factor Receptor Superfamily Market Facts & Figures by Country
- 5.7.1 South America Tumor Necrosis Factor Receptor Superfamily Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Tumor Necrosis Factor Receptor Superfamily Sales by Country (2021-2032)
- 5.7.3 South America Tumor Necrosis Factor Receptor Superfamily Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Tumor Necrosis Factor Receptor Superfamily Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Tumor Necrosis Factor Receptor Superfamily Sales by Type (2021-2032)
- 6.1.1 Global Tumor Necrosis Factor Receptor Superfamily Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Tumor Necrosis Factor Receptor Superfamily Sales Market Share by Type (2021-2032)
- 6.2 Global Tumor Necrosis Factor Receptor Superfamily Revenue by Type (2021-2032)
- 6.2.1 Global Tumor Necrosis Factor Receptor Superfamily Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Tumor Necrosis Factor Receptor Superfamily Revenue Market Share by Type (2021-2032)
- 6.3 Global Tumor Necrosis Factor Receptor Superfamily Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Tumor Necrosis Factor Receptor Superfamily Sales by Application (2021-2032)
- 7.1.1 Global Tumor Necrosis Factor Receptor Superfamily Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Tumor Necrosis Factor Receptor Superfamily Sales Market Share by Application (2021-2032)
- 7.2 Global Tumor Necrosis Factor Receptor Superfamily Revenue by Application (2021-2032)
- 7.2.1 Global Tumor Necrosis Factor Receptor Superfamily Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Tumor Necrosis Factor Receptor Superfamily Revenue Market Share by Application (2021-2032)
- 7.3 Global Tumor Necrosis Factor Receptor Superfamily Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Tumor Necrosis Factor Receptor Superfamily Value Chain Analysis
- 8.1.1 Tumor Necrosis Factor Receptor Superfamily Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Tumor Necrosis Factor Receptor Superfamily Production Mode & Process
- 8.2 Tumor Necrosis Factor Receptor Superfamily Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Tumor Necrosis Factor Receptor Superfamily Distributors
- 8.2.3 Tumor Necrosis Factor Receptor Superfamily Customers
9 Global Tumor Necrosis Factor Receptor Superfamily Analyzing Market Dynamics
- 9.1 Tumor Necrosis Factor Receptor Superfamily Industry Trends
- 9.2 Tumor Necrosis Factor Receptor Superfamily Industry Drivers
- 9.3 Tumor Necrosis Factor Receptor Superfamily Industry Opportunities and Challenges
- 9.4 Tumor Necrosis Factor Receptor Superfamily Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst